NCT00455897View on ClinicalTrials.gov

CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

July 31, 2011

Conditions
Lymphoma, Non-HodgkinLymphoma, B-CellLymphoma, Diffuse
Interventions
DRUG

GM-CSF

Given 11 days before day 1 of cycle 1 for 10 days

DRUG

CHOP

Administered as part of standard care

DRUG

Rituximab

Administered as part of standard treatment

Trial Locations (3)

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

02215

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Bayer

INDUSTRY

lead

Massachusetts General Hospital

OTHER